帕博利珠单抗对比维布妥昔单抗治疗复发/难治性经典型霍奇金淋巴瘤的生活质量分析
KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, or who were ineligible for, autologous stem cell transplantation…
要点
- 帕博利珠单抗组第24周GHS/QoL评分改善,维布妥昔单抗组恶化,组间差异显著。
- 除情感和认知功能外,帕博利珠单抗在QLQ-C30各领域均显示显著改善。
核心结论
- 在KEYNOTE-204研究中,帕博利珠单抗相比维布妥昔单抗在复发/难治性经典型霍奇金淋巴瘤患者中整体改善了健康相关生活质量的患者报告结局。
研究设计与样本
- KEYNOTE-204(NCT02684292)的患者报告结局分析,纳入接受至少1剂研究治疗并完成至少1次PRO评估的患者(帕博利珠单抗n=146,维布妥昔单抗n=150)。
- 使用EORTC QLQ-C30和EQ-5D量表,在基线、每6周至第24周、之后每12周进行评估。
主要发现
- 除情感和认知功能外,帕博利珠单抗在QLQ-C30各领域均观察到显著改善。
关键数值与推荐
- PRO分析集:帕博利珠单抗n=146,维布妥昔单抗n=150;基线依从性>90%,至第24周>80%。
- 预设终点包括基线至第24周的最小二乘均值变化和至真实恶化时间(较基线下降≥10分)。
临床怎么用
- 对于不适合ASCT或ASCT后复发的复发/难治性经典型霍奇金淋巴瘤患者,帕博利珠单抗较维布妥昔单抗可改善健康相关生活质量。
局限性
- 比较采用双侧P值但未控制多重性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, or who were ineligible for, autologous stem cell transplantation (ASCT). Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported from patients who received ≥1 dose of study treatment and completed ≥1 PRO assessment. The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were administered at baseline, every 6 weeks until week 24, and every 12 weeks thereafter. Prespecified end points included least squares mean (LSM) changes from baseline to week 24 and time to true deterioration (TTD; ≥10-point decline from baseline). Comparisons were evaluated using 2-sided P values uncontrolled for multiplicity. High compliance at baseline (>90%) and through week 24 (>80%) was demonstrated across treatment groups (PRO analysis set: pembrolizumab, n = 146; BV, n = 150). The EORTC QLQ-C30 global health status (GHS)/quality of life (QoL) score improved from baseline to week 24 on pembrolizumab and worsened on BV and demonstrated significant LSM differences at 24 weeks (GHS/QoL: 8.60 [95% confidence interval, 3.89-13.31]; P = .0004). Significant improvements were observed in each QLQ-C30 domain except emotional and cognitive functioning. Compared with BV, pembrolizumab prolonged TTD for GHS/QoL (hazard ratio, 0.40 [95% CI, 0.22-0.74]; P = .003) and each QLQ-C30 domain except cognitive functioning. In conclusion, pembrolizumab demonstrated overall improvements in PROs of HRQoL measures over BV in the KEYNOTE-204 study. These data and previously reported efficacy results support pembrolizumab as the preferred treatment option for patients with R/R cHL who are ineligible for or experience relapse after ASCT.
引用
- Zinzani PL, Ramchandren R, Santoro A, et al. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2022. PMID: 34644372. doi:10.1182/bloodadvances.2021004970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。